Park Medi World Limited

NSE: PARKHOSPS · Healthcare

Park Medi World Limited Share Price & Analysis

270.7 -2.97%Updated 21 Jul 2026, 05:01 pm IST
LTP
270.7
-2.97%
Open
High
284.6
Low
269.55
Close
₹270.7
52W High
₹305
52W Low
₹138
Volume
646K
Lot Size
1
Sector
Healthcare
Market Cap
₹12K Cr
Face Value
₹2
Mid Cap

Price Chart

Fundamentals

P/E
45.8
Sector P/E
54.4
P/B
5.57
EPS
₹6.88
ROE
16.7%
ROCE
19.3%
D/E Ratio
0.17
Div Yield
0%
Book Value
₹46.8
+

Strengths

  • Strong return on equity (ROE 16.7%)
  • Efficient capital deployment (ROCE 19.3%)
  • Low debt relative to equity (D/E 0.2x)

Peer Comparison

CompanyCMPMkt CapP/EP/BROE %ROCE %D/E
SUNPHARMA
Sun Pharmaceutical Industries Limited
1,944
₹4.6L Cr37.35.591620.50.07
DIVISLAB
Divi's Laboratories Limited
7,388
₹1.9L Cr73.411.7116.5220.01
TORNTPHARM
Torrent Pharmaceuticals Limited
5,040
₹1.6L Cr73.620.3227.415.20.33
APOLLOHOSP
Apollo Hospitals Enterprise Limited
8,939
₹1.3L Cr64.913.5622.117.90.88
CIPLA
Cipla Limited
1,416
₹1.1L Cr30.13.3211.615.50.01
ZYDUSLIFE
Zydus Lifesciences Limited
1,123
₹1.1L Cr214.1721.221.10.38
LUPIN
Lupin Limited
2,405
₹1.1L Cr19.64.928.729.90.32

Showing 7 peers in the same sector · Sorted by market cap

Financials

Quarterly Results

MetricMar 2026Dec 2025Sep 2025Mar 2025Dec 2024
Revenue
₹460 Cr
▲12.2%
₹410 Cr
▲0.0%
₹410 Cr
▲15.8%
₹354 Cr
▲1.7%
₹348 Cr
Op. Profit
₹127 Cr
▲28.3%
₹99 Cr
▼12.4%
₹113 Cr
▲28.4%
₹88 Cr
▲6.0%
₹83 Cr
OPM
28.0%
▲16.7%
24.0%
▼11.1%
27.0%
▲8.0%
25.0%
▲4.2%
24.0%
Net Profit
₹77 Cr
▲45.3%
₹53 Cr
▼32.9%
₹79 Cr
▲51.9%
₹52 Cr
▲13.0%
₹46 Cr
EPS (₹)
1.64
▲40.2%
1.17
▼38.7%
1.91
▲63.2%
1.17
▼60.6%
2.97

Values in ₹ Cr · Source: Screener.in

Annual Profit & Loss

MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Revenue
₹1.7K Cr
▲20.4%
₹1.4K Cr
▲13.2%
₹1.2K Cr
▼1.9%
₹1.3K Cr
▲15.8%
₹1.1K Cr
▲41.5%
₹766 Cr
Expenses
₹1.2K Cr
▲21.3%
₹1.0K Cr
▲10.8%
₹919 Cr
▲6.5%
₹863 Cr
▲16.6%
₹740 Cr
▲61.9%
₹457 Cr
Op. Profit
₹444 Cr
▲18.4%
₹375 Cr
▲20.2%
₹312 Cr
▼20.2%
₹391 Cr
▲13.3%
₹345 Cr
▲11.7%
₹309 Cr
OPM
26.0%
▼3.7%
27.0%
▲8.0%
25.0%
▼19.4%
31.0%
▼3.1%
32.0%
▼20.0%
40.0%
Other Income
₹32 Cr
▲6.7%
₹30 Cr
▲3.4%
₹29 Cr
▲93.3%
₹15 Cr
▲66.7%
₹9 Cr
▲200.0%
₹3 Cr
Interest
₹59 Cr
▼3.3%
₹61 Cr
▼15.3%
₹72 Cr
▲41.2%
₹51 Cr
▲27.5%
₹40 Cr
▲66.7%
₹24 Cr
Depreciation
₹62 Cr
▲6.9%
₹58 Cr
▲13.7%
₹51 Cr
▲24.4%
₹41 Cr
▲17.1%
₹35 Cr
▲45.8%
₹24 Cr
PBT
₹355 Cr
▲23.7%
₹287 Cr
▲31.7%
₹218 Cr
▼30.8%
₹315 Cr
▲13.3%
₹278 Cr
▲4.9%
₹265 Cr
Tax %
23.0%
▼11.5%
26.0%
▼13.3%
30.0%
▲7.1%
28.0%
▲0.0%
28.0%
▲7.7%
26.0%
Net Profit
₹274 Cr
▲28.6%
₹213 Cr
▲40.1%
₹152 Cr
▼33.3%
₹228 Cr
▲14.6%
₹199 Cr
▲6.4%
₹187 Cr
EPS (₹)
5.98
▲12.0%
5.34
▼46.5%
9.98
▼30.2%
14.29
▲21.5%
11.76
▼85.4%
80.54
Div Payout
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%

Values in ₹ Cr · Source: Screener.in

Balance Sheet

ItemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Liabilities
Equity Capital
₹86 Cr
▲11.7%
₹77 Cr
▲0.0%
₹77 Cr
▲0.0%
₹77 Cr
▲0.0%
₹77 Cr
▲305.3%
₹19 Cr
Reserves
₹1.9K Cr
▲95.0%
₹993 Cr
▲23.2%
₹806 Cr
▲32.1%
₹610 Cr
▲60.5%
₹380 Cr
▲48.4%
₹256 Cr
Borrowings
₹364 Cr
▼46.6%
₹682 Cr
▼0.7%
₹687 Cr
▲19.3%
₹576 Cr
▲11.4%
₹517 Cr
▲77.1%
₹292 Cr
Other Liabilities
₹427 Cr
▲11.8%
₹382 Cr
▲11.4%
₹343 Cr
▲3.6%
₹331 Cr
▲3.8%
₹319 Cr
▲28.1%
₹249 Cr
Total Liabilities
₹2.8K Cr
▲31.8%
₹2.1K Cr
▲11.6%
₹1.9K Cr
▲20.0%
₹1.6K Cr
▲23.2%
₹1.3K Cr
▲58.5%
₹816 Cr
Assets
Fixed Assets
₹1.3K Cr
▲45.8%
₹898 Cr
▲7.3%
₹837 Cr
▲56.2%
₹536 Cr
▲17.0%
₹458 Cr
▲25.5%
₹365 Cr
CWIP
₹123 Cr
▲232.4%
₹37 Cr
▲15.6%
₹32 Cr
▲540.0%
₹5 Cr
▼82.8%
₹29 Cr
▲314.3%
₹7 Cr
Investments
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
Other Assets
₹1.4K Cr
▲15.2%
₹1.2K Cr
▲15.0%
₹1.0K Cr
▼0.9%
₹1.1K Cr
▲30.5%
₹806 Cr
▲81.9%
₹443 Cr
Total Assets
₹2.8K Cr
▲31.8%
₹2.1K Cr
▲11.6%
₹1.9K Cr
▲20.0%
₹1.6K Cr
▲23.2%
₹1.3K Cr
▲58.5%
₹816 Cr

Values in ₹ Cr · Source: Screener.in

Cash Flow Statement

ItemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Operating CF
₹329 Cr
▲72.3%
₹191 Cr
▼48.0%
₹367 Cr
▲84.4%
₹199 Cr
▲28.4%
₹155 Cr
▼30.5%
₹223 Cr
Investing CF
₹-333 Cr
▼265.9%
₹-91 Cr
▼19.7%
₹-76 Cr
▲67.5%
₹-234 Cr
▲5.6%
₹-248 Cr
▼6.4%
₹-233 Cr
Financing CF
₹121 Cr
▲263.5%
₹-74 Cr
▲43.1%
₹-130 Cr
▼13100.0%
₹1 Cr
▼99.4%
₹163 Cr
▲232.7%
₹49 Cr
Net Cash Flow
₹116 Cr
▲346.2%
₹26 Cr
▼83.9%
₹161 Cr
▲573.5%
₹-34 Cr
▼148.6%
₹70 Cr
▲79.5%
₹39 Cr
Free Cash Flow
₹209 Cr
▲216.7%
₹66 Cr
▼77.9%
₹299 Cr
▲182.1%
₹106 Cr
▲65.6%
₹64 Cr
▼25.6%
₹86 Cr

Values in ₹ Cr · Source: Screener.in

Key Ratios History

MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Debtor Days
129d
▼19.9%
161d
▲6.6%
151d
▼10.1%
168d
▲11.3%
151d
▲0.0%
151d
Inventory Days
4d
3d
▲0.0%
3d
▼78.6%
14d
▼70.2%
47d
Days Payable
134d
133d
▲20.9%
110d
▲8.9%
101d
▼16.5%
121d
Cash Conv. Cycle
-2d
▼101.2%
161d
▲666.7%
21d
▼65.6%
61d
▼4.7%
64d
▼16.9%
77d
Working Capital Days
28d
▼9.7%
31d
▲47.6%
21d
▼47.5%
40d
▼33.3%
60d
▲50.0%
40d
ROCE
19.0%
▼5.0%
20.0%
▲0.0%
20.0%
▼35.5%
31.0%
▼18.4%
38.0%

Source: Screener.in · Lower days = better efficiency

Frequently Asked Questions

What is Park Medi World Limited share price today?
Park Medi World Limited (PARKHOSPS) is currently trading at ₹270.7 on NSE, down 2.97% as of the last market session. Prices update daily after market close on MarketNetra.
Is Park Medi World Limited available in F&O (Futures & Options)?
Yes, Park Medi World Limited (PARKHOSPS) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Park Medi World Limited 52-week high and low?
Park Medi World Limited's 52-week high is ₹305 and the 52-week low is ₹138. The current price of ₹270.7 is 11.2% below the 52W high.
What is Park Medi World Limited P/E ratio?
Park Medi World Limited's current P/E ratio is 45.8. This indicates the market is paying ₹45.8 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Park Medi World Limited options?
Park Medi World Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade PARKHOSPS options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.